Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 6/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.42 |
| ▸ | TNKS | O95271 | 6/20 | 0.42 |
| ▸ | WNT3A | P56704 | 4/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276398 | 0.83 | XDH (0.47) | XDHTNKS2TNKSWNT3APARP1 | |
| SCHEMBL10313638 | 0.78 | TSHR (0.54) | XDHTNKS2TNKSWNT3APARP1 | |
| SCHEMBL10313633 | 0.77 | XDH (0.42) | XDHMEN1KMT2A | |
| SCHEMBL10313629 | 0.76 | PI4KA (0.41) | XDH | |
| SCHEMBL5434565 | 0.66 | TNKS2 (0.67) | TNKS2TNKSWNT3APARP1PARP2 | |
| SCHEMBL13019483 | 0.65 | KIF11 (0.54) | — | |
| SCHEMBL8537126 | 0.65 | XDH (1.00) | XDHMEN1KMT2A | |
| SCHEMBL15693144 | 0.64 | TNKS2 (0.56) | TNKS2TNKSWNT3APARP1PARP2 | |
| SCHEMBL323825 | 0.64 | ALDH1A1 (0.43) | — | |
| SCHEMBL4510952 | 0.63 | DHFR (0.65) | TNKS2TNKSWNT3APARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | XDH 8/4885TNKS2 2499/4885TNKS 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.